About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

14.35 -0.00 (-0.03%)
Streaming Delayed Price Updated: 12:38 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amicus Therapeutics, Inc. - Common Stock

News headline image
Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade ↗
On Thursday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, from 78 to 81. 
Via Investor's Business Daily
News headline image
Amicus Therapeutics Stock Sees Improving Market Leadership; Earns 81 RS Rating ↗
On Monday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, to 81, up from 74 a day earlier. 
Via Investor's Business Daily
News headline image
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in the European Union for Adults with Late-onset Pompe Disease (LOPD) 
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark ↗
One key metric to look for in a stock is an 80-plus RS Rating. Amicus Therapeutics stock hit that mark, with a jump from 74 to 82 Friday. 
Via Investor's Business Daily
News headline image
Amicus Therapeutics: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Amicus Therapeutics ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 1, 2023 ↗
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
News headline image
Earnings Preview: Amicus Therapeutics ↗
 
Via Benzinga
News headline image
Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics ↗
The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult  
Via Benzinga
News headline image
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at the Bank of America 2023 Health Care Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
FDA Defers Action On Amicus Therapeutics' Much Awaited Pompe Disease Therapy ↗
 
Via Benzinga
News headline image
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
'I Think You Should Take The Money And Run': Cramer On This Stock Up 52% Over Past Month ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Amicus Therapeutics Inc (NASDAQ: FOLD) is an "ideal spec. 
Via Benzinga
News headline image
Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Recap: Amicus Therapeutics Q3 Earnings ↗
Amicus Therapeutics (NASDAQ:FOLD) reported its Q3 earnings results on Monday, November 7, 2022 at 06:12 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.